<!doctype html>
<html class="no-js" lang="en">

<head>
  <!-- Global site tag (gtag.js) - Google Analytics -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=UA-134228602-13"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());

    gtag('config', 'UA-134228602-13');
  </script>

  <meta charset="utf-8">
  <meta http-equiv="x-ua-compatible" content="ie=edge">
  <title>ğŸ€ ğŸ‘ŠğŸ¿ ğŸ‘ˆğŸ¿ Scientists have found T cells that open up the promise of universal anti-cancer immune therapy ğŸ§˜ğŸ¾ ğŸ§‘ğŸ¾â€ğŸ¤â€ğŸ§‘ğŸ¼ âœ…</title>
  <link rel="icon" type="image/x-icon" href="/favicon.ico" />
  <meta name="description" content="Scientists from the University of Cardiff have discovered a new type of T-killers that give us hope for universal anti-cancer therapy.T-cell therapy -...">
  <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">

  <link rel="stylesheet" href="../../css/main.css">

  <link href="https://fonts.googleapis.com/css?family=Quicksand&display=swap" rel="stylesheet">

  <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.3.1/jquery.min.js"></script>
  <script>window.jQuery || document.write('<script src="../../js/vendors/jquery-3.3.1.min.js"><\/script>')</script>

  <script>document.write('<script src="//pagea' + 'd2.googles' + 'yndication.com/pagea' + 'd/js/a' + 'dsby' + 'google.js"><\/script>')</script>
  <script>
        var superSpecialObject = {};
        superSpecialObject['google_a' + 'd_client'] = 'ca-p' + 'ub-6974184241884155';
        superSpecialObject['enable_page_level_a' + 'ds'] = true;
       (window['a' + 'dsbygoogle'] = window['a' + 'dsbygoogle'] || []).push(superSpecialObject);
  </script>
</head>

<body>
  <!--[if lte IE 9]>
    <p class="browserupgrade">You are using an <strong>outdated</strong> browser. Please <a href="https://browsehappy.com/">upgrade your browser</a> to improve your experience and security.</p>
  <![endif]-->
  <header class="page-header js-page-header">
    <a class="page-header-logo-container" href="https://geek-week.github.io/index.html"></a>
    <div class="page-header-text">Get best of the week</div>
  </header>
  <section class="page js-page"><h1>Scientists have found T cells that open up the promise of universal anti-cancer immune therapy</h1><div class="post__body post__body_full">
      <div class="post__text post__text-html post__text_v1" id="post-content-body" data-io-article-url="https://habr.com/ru/post/486516/"><img src="https://habrastorage.org/webt/ht/zr/he/htzrhekhmlv8120qi6ftnjjdtoa.jpeg"> <br>
<br>
<blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Scientists from the </font></font><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u=" rel="nofollow"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">University of Cardiff</font></font></a><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> have discovered a new type of </font></font><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u=" rel="nofollow"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">T-killers</font></font></a><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> that give us hope for universal anti-cancer therapy.</font></font></blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">T-cell therapy - extracting immune cells, modifying them and returning them to the patientâ€™s blood to search for and destroy cancer cells is the latest paradigm in cancer treatment. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
The most widely used therapy, known as </font></font><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u=" rel="nofollow"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">CAR-T</font></font></a><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> , is personalized for each patient, but targets only a few types of cancer and has not been successful in treating the tumors that make up most cancers.</font></font><br>
<a name="habracut"></a> <br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Cardiff scientists have discovered T cells equipped with a new type of </font></font><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u=" rel="nofollow"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">T cell receptor</font></font></a><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> (TCR) that recognize and kill most types of cancer in humans, while ignoring healthy cells. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
This TCR recognizes a molecule present on the surface of a wide range of cancer cells, as well as in many normal cells of the body, but, surprisingly, it is able to distinguish between healthy and cancer cells, killing only sick people.</font></font><br>
<br>
<h2><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">How does this new TCR work?</font></font></h2> <br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Conventional T cells scan the surface of other cells to find abnormalities and eliminate cancer cells - expressing abnormal proteins - but ignore cells that contain only â€œnormalâ€ proteins. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
The scanning system recognizes small portions of cellular proteins that are associated with cell surface molecules called the </font></font><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u=" rel="nofollow"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">human white blood cell antigen</font></font></a><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> (HLA), allowing T-killers to recognize what is going on inside the cells by scanning their surface.</font></font><br>
<blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">HLA is very different in different people, which previously prevented scientists from creating universal therapy based on T cells, aimed at most types of cancer in all people.</font></font></blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">But a work in Cardiff published </font></font><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u=" rel="nofollow"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">in the journal Nature Immunology</font></font></a><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> describes a unique TCR that can recognize many types of cancer through a single HLA-like molecule called MR1. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Unlike HLA, MR1 does not change in the human population - this means that it is an extremely attractive new target in immunotherapy.</font></font><br>
<br>
<h2><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">What did the scientists show?</font></font></h2> <br>
<blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">It was shown in the work that T cells equipped with the new TCR kill lung, skin, blood, colon, breast, prostate, ovarian, kidney and cervical cancer cells, while ignoring healthy cells.</font></font></blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">To test the therapeutic potential of these cells </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">in vivo</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> , scientists introduced T cells capable of recognizing MR1 in mice with human cancer and the human immune system. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
This showed excellent cancer treatment results, which, according to scientists, were comparable to the CAR-T therapy currently used in the clinic in a similar model in animals.</font></font><blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">The Cardiff team was also able to show that T cells of melanoma patients modified to express this new TCR can destroy not only the patientâ€™s own cancer cells, but also cancer cells of other patients in the laboratory, regardless of the patientâ€™s HLA type.</font></font></blockquote> <br>
<img src="https://habrastorage.org/webt/zu/me/9m/zume9mscmvja9omajlw64f7c9vs.jpeg"> <br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Professor Andrew Sewell, lead author of the study and T-cell expert at Cardiff University School of Medicine, said it was â€œvery unusualâ€ to find a TCR with such broad cancer specificity, and this opened up the prospect of â€œuniversalâ€ cancer therapy. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
â€œWe hope that this new TCR can provide us with a better way to eradicate a wide range of cancers in all people,â€ he said. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
â€œModern treatment methods based on TCR can be used only in a small number of patients and specific cancers.</font></font><blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">â€œTargeting cancer with MR1-specific T cells is an exciting new frontier that opens up the promise of aâ€œ universal â€cancer treatment; </font><font style="vertical-align: inherit;">one type of T cell that can kill many types of cancer in a population. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
"Before, no one believed it was possible."</font></font></blockquote> <br>
<h2><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">And what are their plans?</font></font></h2> <br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Experiments are underway to determine the exact molecular mechanism by which the new TCR distinguishes between cancer and healthy cells. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Scientists believe that it can work by sensing changes in cellular metabolism that cause various metabolic intermediates that appear on the surface of cancer cells using MR1.</font></font><blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">The research team hopes to test this new therapy on patients by the end of this year after safety tests.</font></font></blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Professor Sewell said that a vital aspect of ongoing safety testing is to ensure that T-killers modified by the new TCR recognize only cancer cells. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
â€œThere are many obstacles that need to be overcome, but if testing is successful, I hope that the new treatment can be used in patients after a few years,â€ he said. </font></font><br>
<br>
<img src="https://habrastorage.org/webt/h5/ri/tq/h5ritqsn0kfi2qhkoyaliwkb2ek.jpeg"> <br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Professor Oliver Ottmann, Head of the Department of Hematology, Cardiff University, Department of CAR-T Therapy, said: â€œThis new type of T-cell therapy has enormous potential to overcome the existing limitations of CAR-T, which are struggling to find suitable and safe targets for more than a few types of cancer. â€</font></font><blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Professor Aven Gallimore, Head of the Infections, Immunity and Immunology Department of the </font></font><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u=" rel="nofollow"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Wales Cancer Research Center</font></font></a><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> , said: â€œIf this unique work is correct, it will lay the foundation forâ€œ universal â€T-cell therapy, reducing the considerable costs associated with identifying, generating and growing personalized T -cells.</font></font></blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">â€œThis is an exciting and potentially big step forward in the availability of cancer immunotherapy.â€ </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
The work was funded by the Wellcome Trust, Health and Care Wales and Tenovus research centers. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Professor Kieran Walsh, director of Health and Care Research Wales, said: â€œWe are funding research to make a real difference in people's lives. </font><font style="vertical-align: inherit;">This study is a significant development in the fight against cancer and could change the treatment of thousands of patients. â€</font></font><br>
<br>
<iframe width="560" height="315" src="https://www.youtube.com/embed/YQnzhSsnnDU" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen=""></iframe></div>
      
    </div><p class="reference-to-source js-reference-to-source">Source: https://habr.com/ru/post/undefined/</p>
<section class="more-articles-navigation-panel js-more-articles-navigation-panel">
<h4>More articles:</h4>
<nav class="list-of-articles-container js-list-of-articles-container"><ul class="list-of-pages js-list-of-pages">
<li><a href="../en486500/index.html">Web Components and Open Standards</a></li>
<li><a href="../en486506/index.html">Issue # 30: IT training - current issues and challenges from leading companies</a></li>
<li><a href="../en486510/index.html">Displaying Exception Information Before Emergency Exit</a></li>
<li><a href="../en486512/index.html">Briefly on how to teach Brother MFPs to scan in Windows Server</a></li>
<li><a href="../en486514/index.html">Weekend Reading: 10 materials about replicas of sound cards, open sound libraries and audio software</a></li>
<li><a href="../en486518/index.html">Like 20 years ago</a></li>
<li><a href="../en486528/index.html">This is the norm - 3: normal map types</a></li>
<li><a href="../en486530/index.html">Mainstream. Honorary Workers. Biographical novel</a></li>
<li><a href="../en486532/index.html">Data backup using a bunch of FreeFileSync and 7-zip</a></li>
<li><a href="../en486538/index.html">How I uploaded soft skills online and what it gave me</a></li>
</ul></nav>
</section><br />
<a href="../../allArticles.html"><strong>All Articles</strong></a>
<script src="../../js/main.js"></script>

<!-- Yandex.Metrika counter -->
<script type="text/javascript" >
  (function (d, w, c) {
      (w[c] = w[c] || []).push(function() {
          try {
              w.yaCounter63335242 = new Ya.Metrika({
                  id:63335242,
                  clickmap:true,
                  trackLinks:true,
                  accurateTrackBounce:true,
                  webvisor:true
              });
          } catch(e) { }
      });

      var n = d.getElementsByTagName("script")[0],
          s = d.createElement("script"),
          f = function () { n.parentNode.insertBefore(s, n); };
      s.type = "text/javascript";
      s.async = true;
      s.src = "https://mc.yandex.ru/metrika/watch.js";

      if (w.opera == "[object Opera]") {
          d.addEventListener("DOMContentLoaded", f, false);
      } else { f(); }
  })(document, window, "yandex_metrika_callbacks");
</script>
<noscript><div><img src="https://mc.yandex.ru/watch/63335242" style="position:absolute; left:-9999px;" alt="" /></div></noscript>

<!-- Google Analytics -->
  <script>
    window.ga = function () { ga.q.push(arguments) }; ga.q = []; ga.l = +new Date;
    ga('create', 'UA-134228602-13', 'auto'); ga('send', 'pageview')
  </script>
  <script src="https://www.google-analytics.com/analytics.js" async defer></script>

</section>

<footer class="page-footer">
  <div class="page-footer-legal-info-container page-footer-element">
    <p>
      Geek Week | <span class="page-footer-legal-info-year js-page-footer-legal-info-year">2020</span>
    </p>
  </div>
  <div class="page-footer-counters-container page-footer-element">
    <a class="page-footer-counter-clustrmap" href='#'  title='Visit tracker'><img src='https://clustrmaps.com/map_v2.png?cl=698e5a&w=271&t=t&d=i62cJ2037o_BACd40gCrIso3niu0Sjx2sDFYJkeYdRk&co=3a3a3a&ct=ffffff'/></a>
  </div>
</footer>
  
</body>

</html>